Nagaendran KandiahYee Fai ChanChristopher ChenDarwin DasigJacqueline DominguezSeol Heui HanJianping JiaSang Yun KimPanita LimpawattanaLi Ling NgDinh Toan NguyenPaulus Anam OngEncarnita Raya-AmpilNor'izzati SaedonVorapun SenanarongSiti SetiatiHarjot SinghChuthamanee SuthisisangTong Mai TrangYuda TuranaNarayanaswamy VenketasubramanianFee Mann YongYong Chul YounRalf IhlChung-Ang University HospitalSiriraj HospitalUniversity Medicine and Pharmacy, Hue UniversityKonkuk University Medical CenterRaffles Hospital, SingaporeXuanwu Hospital, Capital Medical UniversitySubang Jaya Medical CentreMakati Medical CenterUniversity of Santo Tomas, ManilaSt. Luke's Medical Center Quezon CityUniversitas Katolik Indonesia Atma JayaUniversitas PadjadjaranUniversitas Indonesia, RSUPN Dr. Cipto MangunkusumoAlexianer Krefeld GmbHUniversiti MalayaNUS Yong Loo Lin School of MedicineFaculty of Medicine, Khon Kaen UniversityKuala Lumpur HospitalNational Neuroscience Institute of SingaporeChangi General HospitalMahidol UniversitySeoul National University College of MedicineDuke-NUSDr Harjot Singh's Neuropsychiatry Centre and HospitalUniversity Medical CenterLee Kong Chian School of Business2022-08-042022-08-042021-02-01CNS Neuroscience and Therapeutics. Vol.27, No.2 (2021), 149-16217555949175559302-s2.0-85097874280https://repository.li.mahidol.ac.th/handle/20.500.14594/78491Background: Mild cognitive impairment (MCI) is a neurocognitive state between normal cognitive aging and dementia, with evidence of neuropsychological changes but insufficient functional decline to warrant a diagnosis of dementia. Individuals with MCI are at increased risk for progression to dementia; and an appreciable proportion display neuropsychiatric symptoms (NPS), also a known risk factor for dementia. Cerebrovascular disease (CVD) is thought to be an underdiagnosed contributor to MCI/dementia. The Ginkgo biloba extract, EGb 761®, is increasingly being used for the symptomatic treatment of cognitive disorders with/without CVD, due to its known neuroprotective effects and cerebrovascular benefits. Aims: To present consensus opinion from the ASian Clinical Expert group on Neurocognitive Disorders (ASCEND) regarding the role of EGb 761® in MCI. Materials & Methods: The ASCEND Group reconvened in September 2019 to present and critically assess the current evidence on the general management of MCI, including the efficacy and safety of EGb 761® as a treatment option. Results: EGb 761® has demonstrated symptomatic improvement in at least four randomized trials, in terms of cognitive performance, memory, recall and recognition, attention and concentration, anxiety, and NPS. There is also evidence that EGb 761® may help delay progression from MCI to dementia in some individuals. Discussion: EGb 761® is currently recommended in multiple guidelines for the symptomatic treatment of MCI. Due to its beneficial effects on cerebrovascular blood flow, it is reasonable to expect that EGb 761® may benefit MCI patients with underlying CVD. Conclusion: As an expert group, we suggest it is clinically appropriate to incorporate EGb 761® as part of the multidomain intervention for MCI.Mahidol UniversityMedicinePharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1111/cns.13536